Title : Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.

Pub. Date : 2021 Oct

PMID : 34510760






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The gefitinib + anlotinib treatment exerted a synergistic antitumor effect by downregulating the activation of VEGFR2 and downstream effectors, Akt and ERK. Gefitinib AKT serine/threonine kinase 1 Homo sapiens